Cargando…

Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon

In August 2002, 65 cases of Loa-associated neurological Serious Adverse Events were reported after ivermectin treatment. The first signs, occurring within the 12–24 hours following treatment, included fatigue, generalized arthralgia, and sometimes agitation, mutism, and incontinence. Disorders of co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boussinesq, Michel, Gardon, Jacques, Gardon-Wendel, Nathalie, Chippaux, Jean-Philippe
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147657/ https://www.ncbi.nlm.nih.gov/pubmed/14975061 http://dx.doi.org/10.1186/1475-2883-2-S1-S4

Ejemplares similares

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa
por: Chesnais, Cédric B., et al.
Publicado: (2020)

Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control
por: Thomson, Madeleine C, et al.
Publicado: (2004)

Effect of a Single Standard Dose (150–200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis
por: Pion, Sébastien D, et al.
Publicado: (2019)

Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually
por: Campillo, Jérémy T., et al.
Publicado: (2020)

Report of a Scientific Working Group on Serious Adverse Events following Mectizan(® ) treatment of onchocerciasis in Loa loa endemic areas
Publicado: (2003)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan(®) treatment of onchocerciasis in Loa loa endemic areas.
por: Duke, Brian OL
Publicado: (2003)

Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators of Loa loa Infection
por: Nana-Djeunga, Hugues C., et al.
Publicado: (2020)

Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?
por: Chandler, Rebecca E.
Publicado: (2018)

“Test and not treat” for onchocerciasis control in a Loa loa endemic area
por: Kamgno, Joseph, et al.
Publicado: (2017)

Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa
por: Wanji, Samuel, et al.
Publicado: (2018)

A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa–coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon
por: Lenk, Edeltraud J, et al.
Publicado: (2020)

Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases
por: Twum-Danso, Nana AY
Publicado: (2003)

Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study
por: Higazi, Tarig B, et al.
Publicado: (2004)

Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon
por: Kouam, Marc K, et al.
Publicado: (2013)

Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness
por: Walker, Martin, et al.
Publicado: (2017)

Feasibility of Onchocerciasis Elimination Using a “Test-and-not-treat” Strategy in Loa loa Co-endemic Areas
por: Blok, David J, et al.
Publicado: (2020)

Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future
por: Twum-Danso, Nana AY
Publicado: (2003)

Genetic Selection of Low Fertile Onchocerca volvulus by Ivermectin Treatment
por: Bourguinat, Catherine, et al.
Publicado: (2007)

Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin
por: Siewe Fodjo, Joseph Nelson, et al.
Publicado: (2018)

Assessing Hypoendemic Onchocerciasis in Loa loa Endemic Areas of Southeast Nigeria
por: Rakers, Lindsay J., et al.
Publicado: (2020)

Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis
por: Haselow, Nancy J, et al.
Publicado: (2003)

Mapping lymphatic filariasis in Loa loa endemic health districts naïve for ivermectin mass administration and situated in the forested zone of Cameroon
por: Beng, Andrew A., et al.
Publicado: (2020)

Geostatistical modelling enables efficient safety assessment for mass drug administration with ivermectin in Loa loa endemic areas through a combined antibody and LoaScope testing strategy for elimination of onchocerciasis
por: Johnson, Olatunji, et al.
Publicado: (2022)

Unusual Localization of Blood-Borne Loa loa Microfilariae in the Skin Depends on Microfilarial Density in the Blood: Implications for Onchocerciasis Diagnosis in Coendemic Areas
por: Niamsi-Emalio, Yannick, et al.
Publicado: (2021)

Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria
por: Brieger, William R, et al.
Publicado: (2011)

Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon
por: Boullé, Charlotte, et al.
Publicado: (2019)

Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study
por: Pion, Sébastien DS, et al.
Publicado: (2020)

Temporal variability of Loa loa microfilaraemia
por: Campillo, Jérémy T., et al.
Publicado: (2023)

Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
por: Mackenzie, Charles D, et al.
Publicado: (2003)

Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis
por: Kelly-Hope, Louise, et al.
Publicado: (2017)

Factors associated with the periodicity of Loa loa microfilaremia in the Republic of the Congo
por: Campillo, Jérémy T., et al.
Publicado: (2022)

Molecular Epidemiology of Blood-Borne Human Parasites in a Loa loa-, Mansonella perstans-, and Plasmodium falciparum-Endemic Region of Cameroon
por: Drame, Papa M., et al.
Publicado: (2016)

Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World
por: Campillo, Jérémy T., et al.
Publicado: (2021)

Fifteen Years of Annual Mass Treatment of Onchocerciasis with Ivermectin Have Not Interrupted Transmission in the West Region of Cameroon
por: Katabarwa, Moses N., et al.
Publicado: (2013)

Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon
por: Kamga, Guy-Roger, et al.
Publicado: (2018)

The Mbam drainage system and onchocerciasis transmission post ivermectin mass drug administration (MDA) campaign, Cameroon
por: Abong, Raphael Awah, et al.
Publicado: (2021)

A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy
por: Lukiana, Tuna, et al.
Publicado: (2006)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

Prevalence of onchocerciasis in the Fundong Health District, Cameroon after 6 years of continuous community-directed treatment with ivermectin
por: Kamga, Henri Lucien Fouamno, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lr4vv5lncgsv9lepip8gdca1l6